Abstract:Ferroptosis, an iron-dependent form of regulated cell death, plays a crucial role in modulating the therapeutic response in non-small cell lung cancer (NSCLC) patients. Studies have identified the signal transducer and activator of transcription 3 (STAT3) and myeloid cell leukemia-1 (MCL1) as potential targets for sorafenib, which exhibits activities in inducing ferroptosis. However, the role of STAT3-MCL1 axis in sorafenib-induced ferroptosis in NSCLC is still unclear. This study provided evidence that ferroptosis is a critical driver of sorafenib-induced cell death in NSCLC, supported by the accumulation of lipid peroxidation products, indicative of oxidative stress-induced cell death. Additionally, both in vitro and in vivo experiments showed that ferroptosis contributed to a significant portion of the anti-cancer effects elicited by sorafenib in NSCLC. The noticeable accumulation of lipid peroxidation products in sorafenib-treated mice underscored the significance of ferroptosis as a contributing factor to the therapeutic response of sorafenib in NSCLC. Furthermore, we identified the involvement of the STAT3/MCL1 axis in sorafenib-induced antitumor activity in NSCLC. Mechanistically, sorafenib inhibited endogenous STAT3 activation and downregulated MCL1 protein expression, consequently unleashing the ferroptosis driver BECN1 from the BECN1-MCL1 complex. Conversely, there is an augmented association of BECN1 with the catalytic subunit of system Xc − , SLC7A11, whose activity to import cystine and alleviate lipid peroxidation is hindered upon its binding with BECN1. Notably, we found that MCL1 upregulation correlated with ferroptosis resistance in NSCLC upon sorafenib treatment. Our findings highlight the importance of sorafenib-triggered ferroptosis in NSCLC and offer a novel strategy to treat advanced NSCLC patients: by downregulating MCL1 and, in turn, predispose NSCLC cells to ferroptosis.

STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.

STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis bythe protein kinase inhibitor sorafenib

Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF‐1α/SLC7A11 pathway

The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis

Sorafenib with ASC-J9® Synergistically Suppresses the HCC Progression Via Altering the Pstat3-Ccl2/bcl2 Signals.

Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.

Inflammatory Microenvironment of Fibrotic Liver Promotes Hepatocellular Carcinoma Growth, Metastasis and Sorafenib Resistance Through STAT3 Activation.

Coordinative Activities of STAT3 Inhibitor BP-1-102 and Sorafenib Against Proliferation, Angiogenesis and EMT in Hepatocellular Carcinoma

Targeting Tumor-Infiltrating Ly6G+ Myeloid Cells Improves Sorafenib Efficacy in Mouse Orthotopic Hepatocellular Carcinoma.

Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis

Differential Effects of Sorafenib on Liver Versus Tumor Fibrosis Mediated by Stromal-Derived Factor 1 Alpha/c-X-c Receptor Type 4 Axis and Myeloid Differentiation Antigen-Positive Myeloid Cell Infiltration in Mice.

Sorafenib: A Potential Therapeutic Drug for Hepatic Fibrosis and Its Outcomes.

CCT3 drives Sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC

Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity.

Sorcin Inhibits Mitochondrial Apoptosis by Interacting with STAT3 via NF-κB Pathway

Increasing AR by HIF-2α Inhibitor (PT-2385) Overcomes the Side-Effects of Sorafenib by Suppressing Hepatocellular Carcinoma Invasion Via Alteration of Pstat3, Pakt and Perk Signals

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance Through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma

Retraction Note: Combination of Sorafenib and Gadolinium Chloride (gdcl3) Attenuates Dimethylnitrosamine(dmn)-Induced Liver Fibrosis in Rats

Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration

A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction